Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)

Technology appraisal
Reference number: TA941
Published: 20 December 2023

History

Invitation to participate

Final scope (PDF 165 KB)

Published:

17 March 2023
Final stakeholder list (PDF 164 KB)

Published:

17 March 2023
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 278 KB)

Published:

17 March 2023
Equality impact assessment (Scoping) (PDF 125 KB)

Published:

17 March 2023

Topic selection

Topic selection
Supporting documentation (MSWord 50 KB)

Published:

07 March 2023

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5105

Draft matrix post referral (PDF 161 KB)

Published:

21 September 2022
Draft scope post referral (PDF 167 KB)

Published:

21 September 2022

Topic selection

Topic selection